Literature DB >> 31612462

The pharmacology of itch.

J R Ingram1, A Ahluwalia2.   

Abstract

The article has been co-published with permission in British Journal of Dermatology and British Journal of Pharmacology. The articles are identical except for minor stylistic and spelling differences in keeping with each journal's style. Either citation can be used when citing this article.
© 2019 British Association of Dermatologists and British Pharmacological Society.

Year:  2019        PMID： 31612462      PMCID： PMC6932938          DOI： 10.1111/bph.14865

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  14 in total

1.  Oiling the wheels of discovery.

Authors:  Roderick J Flower
Journal:  Br J Pharmacol       Date:  2019-04       Impact factor: 8.739

Review 2.  Pruritus secondary to primary biliary cholangitis: a review of the pathophysiology and management with phototherapy.

Authors:  A B Hussain; R Samuel; V S Hegade; D E Jones; N J Reynolds
Journal:  Br J Dermatol       Date:  2019-07-28       Impact factor: 9.302

3.  A multiyear cross-sectional study of U.S. national prescribing patterns of first-generation sedating antihistamines in older adults with skin disease.

Authors:  I Cenzer; N Nkansah-Mahaney; M Wehner; M M Chren; T Berger; K Covinsky; K Berger; K Abuabara; E Linos
Journal:  Br J Dermatol       Date:  2019-07-21       Impact factor: 9.302

4.  Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data.

Authors:  L E M de Wijs; A L Bosma; N S Erler; L M Hollestein; L A A Gerbens; M A Middelkamp-Hup; A C M Kunkeler; T E C Nijsten; P I Spuls; D J Hijnen
Journal:  Br J Dermatol       Date:  2019-10-16       Impact factor: 9.302

Review 5.  The role of the histamine H4 receptor in atopic dermatitis and psoriasis.

Authors:  Katrin Schaper-Gerhardt; Kristine Rossbach; Eirini Nikolouli; Thomas Werfel; Ralf Gutzmer; Susanne Mommert
Journal:  Br J Pharmacol       Date:  2019-01-02       Impact factor: 8.739

Review 6.  Substance P and neurokinin 1 receptor are new targets for the treatment of chronic pruritus.

Authors:  S Ständer; G Yosipovitch
Journal:  Br J Dermatol       Date:  2019-06-06       Impact factor: 9.302

7.  COX-2-selective inhibitors celecoxib and deracoxib modulate transient receptor potential vanilloid 3 channels.

Authors:  Stefan Spyra; Anne Meisner; Michael Schaefer; Kerstin Hill
Journal:  Br J Pharmacol       Date:  2017-06-29       Impact factor: 8.739

8.  The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study.

Authors:  R Bissonnette; C Maari; S Forman; N Bhatia; M Lee; J Fowler; S Tyring; D Pariser; H Sofen; S Dhawan; M Zook; D J Zammit; H Usansky; L Denis; N Rao; T Song; A B Pavel; E Guttman-Yassky
Journal:  Br J Dermatol       Date:  2019-05-06       Impact factor: 9.302

Review 9.  Histamine, histamine receptors, and neuropathic pain relief.

Authors:  Ilona Obara; Vsevolod Telezhkin; Ibrahim Alrashdi; Paul L Chazot
Journal:  Br J Pharmacol       Date:  2019-06-07       Impact factor: 8.739

10.  TRPA1 activation leads to neurogenic vasodilatation: involvement of reactive oxygen nitrogen species in addition to CGRP and NO.

Authors:  Aisah A Aubdool; Xenia Kodji; Nayaab Abdul-Kader; Richard Heads; Elizabeth S Fernandes; Stuart Bevan; Susan D Brain
Journal:  Br J Pharmacol       Date:  2016-06-21       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.